In December 2020, AstraZeneca said it was acquiring Alexion, the world’s largest drugmaker focused on developing treatments for rare diseases.
Aradhana Sarin, MD, who is currently Alexion’s executive vice president and CFO, will replace Marc Dunoyer as AstraZeneca’s CFO.
Mr. Dunoyer will retire from AstraZeneca’s board and step down as its CFO, a role he has served in for more than seven years. He will become AstraZeneca’s chief strategy officer and Alexion’s CEO.
All executive changes are conditional upon the acquisition’s closing. AstraZeneca said they will take effect in the third quarter of 2021, when the deal is expected to close.
